Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.58 |
| ▸ | CA2 | P00918 | 10/20 | 0.58 |
| ▸ | CA9 | Q16790 | 10/20 | 0.58 |
| ▸ | CA12 | O43570 | 7/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832876 | 0.94 | PTGS2 (0.58) | CA1CA2CA9CA12CHRNA7 | |
| SCHEMBL4841032 | 0.86 | CA2 (0.53) | CA1CA2CA9CA12CHRNA7 | |
| SCHEMBL4842591 | 0.86 | PTGS2 (0.60) | CA1CA2CA9CA12CHRNA7 | |
| SCHEMBL4844792 | 0.86 | PTGS2 (0.60) | CA1CA2CA9CA12CHRNA7 | |
| SCHEMBL4842319 | 0.86 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL1573850 | 0.83 | TSHR (0.50) | GAAKMT2A | |
| SCHEMBL4832866 | 0.83 | PTGS2 (0.53) | CA1CA2CA9CA12CHRNA7 | |
| SCHEMBL4838223 | 0.76 | PTGS2 (0.44) | PTGS2GAAKDM4E | |
| SCHEMBL13800067 | 0.74 | MAOA (0.44) | GAAKMT2A | |
| SCHEMBL4837353 | 0.74 | PTGS2 (0.60) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399760-B2 | 1-(4-Methylsulfanyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;cyclooxygenase and prostaglandin inhibitor; tumor necrosis factor and interleukins 1, 6, 8, 12 antagonist; | BEXEL PHARMACEUTICALS INC. (US) | 2008-07-15 | — | — | US | claimed |
| US-7101873-B2 | Pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-08-31 | — | — | US | claimed |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-01-15 | — | — | US | claimed |
| WO-2003084937-A2 | PYRIMIDINEDIONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | claimed |
| US-7399760-B2 | 1-(4-Methylsulfanyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;cyclooxygenase and prostaglandin inhibitor; tumor necrosis factor and interleukins 1, 6, 8, 12 antagonist; | BEXEL PHARMACEUTICALS INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7101873-B2 | Pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-01-15 | — | — | US | disclosed |
| WO-2003084937-A2 | PYRIMIDINEDIONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009975-A1 | Novel pyrimidinedione derivatives | TYMS, DPYD, TYMP | CA1 4797/4885CA2 4631/4885CA9 4791/4885 |
| US-20060194799-A1 | Novel pyrimidinedione derivatives | TYMS, TYMP, DPYD | CA1 4812/4885CA2 4639/4885CA9 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.